VERAXA Biotech Appoints Dr. Christoph Erkel as CSO to Advance BiTAC® Cancer Therapy Platform

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has appointed antibody therapeutics researcher Christoph Erkel, Ph.D., as Chief Scientific Officer, reinforcing the company's focus on advancing its proprietary BiTAC® technology platform as it prepares its lead oncology programs for clinical development. The announcement comes at a time when the biotechnology company is moving several elements of its research pipeline forward while expanding its scientific and regulatory capabilities.

According to the company, Dr. Erkel previously served as Vice President of Research & Development, where he helped oversee development of VERAXA's antibody therapeutics portfolio. In his new role, he will lead scientific strategy across the company's BiTAC® platforms and broader oncology pipeline while directing efforts to accelerate product candidates toward clinical studies.

VERAXA is building a diversified oncology pipeline that includes conditionally active T-cell engagers, bispecific ADCs and other engineered antibody therapeutics. Recent regulatory feedback from Germany's Paul-Ehrlich-Institute has provided additional clarity for development of the company's lead BiTAC®-TCE program, marking a key milestone as the company transitions from preclinical research to clinical development.

The appointment of Dr. Erkel underscores VERAXA's commitment to advancing next-generation immunotherapies that seek to improve efficacy while reducing treatment-related toxicity. Investors are closely watching companies like VERAXA that are developing novel approaches to cancer treatment, particularly those focusing on bispecific antibodies and T-cell engagers.

Dr. Erkel's expertise in antibody therapeutics is expected to be instrumental as VERAXA navigates the regulatory landscape and moves its BiTAC® platform toward clinical trials. The company's lead BiTAC®-TCE program has received regulatory feedback that provides a clearer path forward, potentially accelerating the timeline for first-in-human studies.

VERAXA's technology platform is designed to address key limitations of traditional cancer immunotherapies, such as on-target off-tumor toxicity and limited efficacy in solid tumors. By engineering conditionally active T-cell engagers and bispecific ADCs, the company aims to create therapies that are more precise and better tolerated by patients.

The latest news and updates relating to VRXA are available in the company's newsroom at https://ibn.fm/VRXA. For more information on VERAXA Biotech and its BiTAC® platform, visit the company's website.

Forward-looking statements in this press release involve risks and uncertainties. Please see full terms of use and disclaimers on the InvestorBrandNetwork website at http://IBN.fm/Disclaimer.